What is the future for PD pathway inhibitors in combination with platinum-based doublets as frontline therapy for advanced NSCLC?

DAVID ROSS CAMIDGE, MD, PHD, of the University of Colorado Denver answers the question what is the future for PD pathway inhibitors in combination with platinum-based doublets as frontline therapy for advanced NSCLC?